Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial

European Urology

Volumn 62, Issue 2, 2012, Pages 204-209

  Vickers, Andrew ^a   Bennette, Caroline ^b   Steineck, Gunnar ^c   Adami, Hans Olov ^d   Johansson, Jan Erik ^e   Bill Axelson, Anna ^f   Palmgren, Juni ^c   Garmo, Hans ^g,h   Holmberg, Lars ^g,h  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h Regional Cancer Centre Uppsala Orebro   (Sweden)

Author keywords

Prostatectomy; Prostatic neoplasms; Randomized controlled trial; Statistics and research design

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURGERY; COMORBIDITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SCANDINAVIA; STATISTICAL ANALYSIS; STATISTICAL MODEL; SURGICAL MORTALITY; WATCHFUL WAITING;

AGED; BIOPSY; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; NEOPLASM GRADING; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK; TREATMENT OUTCOME;

EID: 84862877628     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.04.024     Document Type: Article

References (21)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. Comparative effectiveness of therapies for clinically localized prostate cancer. Agency for Healthcare Research and Quality Web site. AHRQ Pub. No. 08-EHC010-1. http://www.effectivehealthcare.ahrq.gov/ehc/products/9/79/2008- 0204ProstateCancerExecSum.pdf.
3. A. Bill-Axelson, L. Holmberg, and F. Filen Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial J Natl Cancer Inst 100 2008 1144 1154
4. H.B. Carter, A. Kettermann, and C. Warlick Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359 2364 discussion 64-5
5. L. Klotz Active surveillance for prostate cancer: patient selection and management Curr Oncol 17 Suppl 2 2010 S11 S17
6. L. Klotz, L. Zhang, A. Lam, R. Nam, A. Mamedov, and A. Loblaw Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer J Clin Oncol 28 2010 126 131
7. A. Adamy, D.S. Yee, and K. Matsushita Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer J Urol 185 2011 477 482
8. N.J. van As, N.M. de Souza, and S.F. Riches A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance Eur Urol 56 2009 981 988
9. P.P. Glasziou, and L.M. Irwig An evidence based approach to individualising treatment BMJ 311 1995 1356 1359
10. J. Hadley, K.R. Yabroff, M.J. Barrett, D.F. Penson, C.S. Saigal, and A.L. Potosky Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data J Natl Cancer Inst 102 2010 1780 1793
11. M.R. Cooperberg, D.P. Lubeck, S.S. Mehta, and P.R. Carroll Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol 170 2003 S21 S25 discussion S6-7
12. P.C. Albertsen, J.A. Hanley, and G.H. Barrows Prostate cancer and the Will Rogers phenomenon J Natl Cancer Inst 97 2005 1248 1253 (Pubitemid 41535365)
13. T.J. Wilt, R. MacDonald, I. Rutks, T.A. Shamliyan, B.C. Taylor, and R.L. Kane Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer Ann Intern Med 148 2008 435 448 (Pubitemid 351665443)
14. J.H. Hayes, D.A. Ollendorf, and S.D. Pearson Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis JAMA 304 2010 2373 2380
15. C. von Bodman, G. Godoy, and D.C. Chade Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy J Urol 184 2010 143 148
16. A.J. Vickers, C.J. Savage, and M. Hruza The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study Lancet Oncol 10 2009 475 480
17. A.J. Vickers, F.J. Bianco, and A.M. Serio The surgical learning curve for prostate cancer control after radical prostatectomy J Natl Cancer Inst 99 2007 1171 1177 (Pubitemid 47233067)
18. M.A. Dall'Era, B.R. Konety, and J.E. Cowan Active surveillance for the management of prostate cancer in a contemporary cohort Cancer 112 2008 2664 2670 (Pubitemid 351969209)
19. M.R. Cooperberg, J.E. Cowan, and J.F. Hilton Outcomes of active surveillance for men with intermediate-risk prostate cancer J Clin Oncol 29 2011 228 234
20. P.J. Bastian, B.H. Carter, and A. Bjartell Insignificant prostate cancer and active surveillance: from definition to clinical implications Eur Urol 55 2009 1321 1332
21. L.A. Siminoff, N.H. Gordon, P. Silverman, T. Budd, and P.M. Ravdin A decision aid to assist in adjuvant therapy choices for breast cancer Psychooncology 15 2006 1001 1013 (Pubitemid 44762705)